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Open access under CC Ba b s t r a c tAvailable online 13 August 2008 T-cell interferon-gamma release assays (IGRAs) are more speciﬁc and probably more sensitive
than the tuberculin skin test (TST) for the diagnosis of latent tuberculosis infection (LTBI). Patients
with immune-mediated inﬂammatory diseases (IMID) and suspected LTBIwho are candidates for
anti-TNF therapy are at a signiﬁcant risk of TB reactivation yet are prone to false-negative TST
results because theyare already on immunosuppressivemedications. The role of these newblood
tests in this patient population is therefore of considerable interest but is currently unclear. The
limited published evidence-base shows that agreement between IGRA and TST results is poor in
patients with IMID compared to patients without IMID, due to lower proportions of TST-positive
results in patients with IMID. Discordant TST-positive, IGRA-negative results are associated with
prior BCG vaccination and discordant TST-negative, IGRA-positive results are associated with
steroid therapy. Notably, positive IGRA results are more closely associated with the presence of
risk factors for LTBI than TST. The percentage of indeterminate IGRAs can be up to 12%. IGRA
results in patients already taking anti-TNF agents currently remain uninterpretable. Given the
clinical imperative to prevent reactivation of TB in patients starting anti-TNF therapy, screening
algorithms should maximise diagnostic sensitivity for detection of LTBI. Therefore, a positive
result to either an IGRA or TST, in addition to currently recommended clinical screening for risk
factors for LTBI, should prompt consideration of preventive treatment of LTBI in this population.
© 2008 Elsevier B.V. Open access under CC BY license.Keywords:
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Y license.1. The risk of incident tuberculosis during anti-TNF
therapy
Therapeutic blockade of tumour necrosis factor alpha (TNF)
has emerged as an effective treatment in immune-mediated
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ankylosing spondylitis, Crohn's disease and psoriatic arthritis.
However, TNFα is a key cytokine in protective host defence
against Mycobacterium tuberculosis (M. tuberculosis) and, toge-
ther with TNF-dependent chemokines [34] play an important
role in the development and maintenance of the granuloma
which compartmentalises tubercle bacilli during infection
[35,36] (Fig. 1). Inhibition of TNFα and TNF-regulated chemo-
kinenetworks is thepresumedbiological basis for the 4 to 5 fold
higher incidence of tuberculosis observed after initiation of
anti-TNF therapy with inﬂiximab, in patients latently infected
with M. tuberculosis [1–3]. It remains unclear though, despite
there being case reports,whether theTNFα receptor antagonist,
etanercept, or the fully humanised monoclonal antibody,
adalimumab, increases the risk of TB above the elevated base-
line TB incidence rates already documented for patients with
rheumatoid arthritis (RA) [4,5,37]. Development of active TB
once inﬂiximab treatment is started is rapid, with a median
onsetof 12weeks and98%of casesoccurringwithin6monthsof
initiation of TNF blockade [1]. Moreover, there is a higher
incidence of life-threatening extrapulmonary and disseminated
disease than among immunocompetent patients. Exclusion of
active TB and treatment of latent tuberculosis infection (LTBI)
are therefore clinical imperatives prior to starting anti-TNF
therapy and active surveillance for a history of untreated or
partially treated TB or LTBI has already been shown to be effec-
tive in reducing the number of incident TB cases [2,3].
2. Current clinical practice
In the absence of a gold standard test for diagnosis of LTBI,
current clinical management of patients with IMID requiring
anti-TNF therapy involves checking for a history of untreated or
partially treated TB, risk-stratiﬁcation for exposure to cases of
active TB, evidence of residual changes indicative of prior TB
infection on a chest radiograph and a tuberculin skin test (TST).
The TST is a measure of the delayed-type hypersensitivity
reaction to intradermal inoculation of puriﬁed proteinFig. 1. Schematic representation of the essential role of TNFα in host immunity agai
tuberculosis is 4 to 5 fold higher after initiation of anti-TNF therapywith inﬂiximab. How
fully humanisedmonoclonal antibody, adalimumab, increases the risk of TB above the ederivative (PPD), a crude mixture of more than 200 M.
tuberculosis proteins. Because antigens within PPD are also
found in other mycobacteria, the TST suffers from poor
speciﬁcity in bacille Calmette–Guérin (BCG)-vaccinated per-
sons. Moreover, the sensitivity of the tuberculin skin test used
to diagnose LTBI is compromised in patients on immunosup-
pressive therapy with a high rate of false-negative TST test
results. For example, in a Peruvian study, the size of the TST
response was signiﬁcantly lower and the proportion negative
(i.e. b5 mm) to TST was signiﬁcantly higher in patients with
RA compared to healthy immunocompetent controls (median
size PPD induration 4.5 vs 11.5 mm Pb0.01; 79/112 (70.6%) vs
25/96 (26%) Pb0.01, respectively) [6]. Logistical hurdles,
including the need for a return visit to read the result of this
in vivo test and operator variability in inoculation and reading
of the result, also limit the effective use of TST.
Thus because almost all patients awaiting initiation of anti-
TNF therapy are on immunosuppressive therapy [1], the TST is
not an appropriate test to screen for LTBI in patients with
chronic inﬂammatory diseases. This concern around the
interpretation of the TST in patients on disease modifying
antirheumatic drugs (DMARDs) is reﬂected in British Thoracic
Society guidelines from 2005 that recommended replacing TST
with an individual risk–beneﬁt calculation in patients with a
normal chest radiograph balancing the population risk of LTBI
in different groups based on age and ethnicity with the risk of
serious hepatotoxicity secondary to isoniazid therapy [7].
3. T-cell interferon-gamma release assays
T-cell interferon-gamma release assays (IGRAs) have been
developed as an alternative immunodiagnostic approach to the
TST for detecting M. tuberculosis infection [8–11]. Two assay
formats are used to detect ex vivo either the frequency of pre-
sensitised M. tuberculosis-speciﬁc T cells releasing interferon-
gamma (IFN-γ) isolated from peripheral blood mononuclear
cells (ELISpot) or the amount of IFN-γ released in whole blood
(ELISA) in response to the immunodominant secreted proteinsnst M. tb infection. In patients latently infected with M. tb the risk of inciden
ever, it remains unclearwhether the TNFα receptor antagonist, etanercept, or the
levated baseline TB incidence rates already documented for patients with IMIDst
.
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protein 10 (CFP-10). The ELISpot assay developed by Lalvani
[8,12–16] is commercially available as T-SPOT™.TB (Oxford
Immunotec, Abingdon, U.K.), and the ELISA is commercially
available as either QuantiFERON™-TB Gold (QFT-G, Cellestis,
Carnegie, Australia) or QuantiFERON™-TB Gold in-tube (QFT-IT,
Cellestis, Carnegie, Australia) which has the additional antigen
TB7.7 encoded by a phage-inserted region, RD11.
The antigens used in IGRAs are absent from BCG [17] and
most environmental mycobacteria (except M. kansasii, M.
szulgai, M. marinum, M. ﬂavescens and M. gastrii) [18]. Thus
T-cell responses to these antigens are not confounded by prior
BCG vaccination and are a more speciﬁc immunemarker ofM.
tuberculosis infection than TST. Moreover, IGRAs are probably
more sensitive thanTST for diagnosing LTBI. If they prove to be
more sensitive in patients with IMID who are prone to false-
negative TST results and who are candidates for immunosup-
pressive medications that increase the risk of TB reactivation
they will have high clinical utility in routine rheumatological
practice. Here we review the evidence-base to date on the
performance of IGRAs in these patients.
4. Clinical performance of IGRAs in patients with IMID
before anti-TNF therapy
Published data on IGRAperformance in the diagnosis of LTBI
in IMID is scarce but expanding rapidly (Table 1). IGRAs
performance in patients with IMID has been based on
agreement of results with the TST and on the relative strength
of the association of TST and IGRA results with risk factors for
LTBI. The former type of study design is less useful than theTable 1
Study, reference Assay No. patients
with IMID
Main ﬁndings
Bocchino
et al. [38]
QFT-IT T-SPOT.TB 66 8/15 patients with IMID and risk
remaining 7 were negative to TS
without risk factors for TB infec
Ponce de Leon
et al. [22]
QFT-IT 101 Proportion of TST-positive resul
(27/101 (26.7%) vs 61/93 (65.6%)
Pb0.001) Proportion TST-positiv
lower than proportion QFT-IT-po
Difference in proportion TST-pos
but not in healthy controls (P=0
Agreement between QFT-IT & TS
Agreement between QFT-IT & TS
Vassilopoulos
et al. [24]
T-SPOT.TB 70 Agreement between TST and T-S
On multivariate analysis BCG wa
On multivariate analysis steroid
Matulis
et al. [19]
QFT-IT 142 QFT-IT associated more closely w
OR 2.77 (95% CI 1.22 to 6.27 P=0
Odds QFT-IT-positive result incr
QFT-IT associated less closely wi
(95% CI 0.74 to 8.01) P=0.025)
Agreement between QFT-IT & TS
Cobanoglu
et al. [20]
QFT-IT 68 Agreement between TST & QFT-
Agreement between TST & QFT-
Takahashi
et al. [21]
QFT-G 14 Agreement between convention
QFT-G results was moderate (64
Sellam
et al. [23]
T-SPOT.TB 7 Agreement between TST and T-S
primo-infection, previous TB wi
(independent of TST) was mode
Pratt
et al. [25]
QFT-G 101 7/101 (7%) patients with rheum
No cases of M. tuberculosis react
following initiation anti-TNF trelatter. Data from studies that is not correlated with surrogate
markers of LTBI collectively concludes that (a) agreement
between TST and IGRA is poor and weaker in patients with
IMID than in healthy controls due to lower proportions of TST-
positive results in patients with IMID [19–24], (b) the
magnitude of the TST response is signiﬁcantly lower in patients
with IMID than in healthy controls [22], (c) that discordant TST-
positive, IGRA-negative results are associated with prior BCG
vaccination [24] and that (d) discordant TST-negative, IGRA-
positive results are associated with steroid therapy [24].
Only two studies to date have correlated IGRA and TST
results with risk factors for LTBI. In 142 patients with IMID,
QuantiFERON®-TB Gold in-tubewas signiﬁcantly more closely
associated with the presence of risk factors for LTBI than TST
whereas TST was signiﬁcantly more closely associated with
BCG vaccination than QuantiFERON®-TB Gold in-tube [19].
Moreover, the odds of a positive QuantiFERON®-TB Gold in-
tube result, but not TST result, increased with increasingly
relevant prognostic risk factors for LTBI from born or resident
in a high prevalence country to a history of active tuberculosis.
In the second study, IGRAs were positive in 7 TST-negative
patients with IMID and risk factors for TB infection [38].
The only gold standard for LTBI is the subsequent de-
velopment of TB but the generation of such data requires large
longitudinal clinical outcome studies to establish the prognos-
tic value of positive test results. The only published prospective
data to date is too small to be able to draw any conclusions,
comprising follow-up of 7 RA patients with positive Quanti-
FERON®-TB Gold results, 4 of whom subsequently started anti-
TNF agents, for between 6 and 30months, but none developed
active TB [25].factors for TB infection were positive to TST, T-SPOT.TB and QFT-IT. The
T but positive to either T-SPOT.TB and/or QFT-IT. 35/51 patients with IMID
tion were negative to TST, T-SPOT.TB and QFT-IT.
ts was signiﬁcantly less in patients with IMID than in healthy controls
Pb0.001) and size TST response signiﬁcantly less (mean 3.73 vs 11.0 mm
e results in patients with IMID was 41% of healthy controls, signiﬁcantly
sitive results in patients with IMIDs was 75% of healthy controls (P = 0.008)
itive & QFT-IT-positive was signiﬁcant in patients with IMID (P=0.013)
.45)
T results was poor in patients with IMID (agreement 70% k=0.37)
T results was good in healthy controls (n=93, agreement 83% k=0.64)
POT.TB results was moderate (72.8%)
s associated with TST-positive ELISpot-negative results (P=0.01)
use was associated with TST-negative ELISpot-positive results (P=0.04)
ith presence risk factors for LTBI than TST (OR 23.8 (95% CI 5.14 to 110 vs
.009).
eased with increasingly relevant markers of LTBI risk factors.
th BCG than TST (OR 0.47 (95% CI 0.15 to 1.47) vs OR 2.44
T results was low (agreement 64% k=0.17 (95% CI 0.02 to 0.32))
IT results in patients with IMID was poor (agreement 47% & 55% k=0.18)
IT results in healthy controls (n=38) was poor (agreement 64% k=−0.54)
al diagnosis for LTBI (TST, chest radiography & medical history) and
.3%).
POT.TB results in patients with IMID with conﬁrmed LTBI based on previous
th inadequate treatment or TB lesions on chest radiograph
rate (71%).
atoid arthritis were QFT-G-positive. 4/7 were started on anti-TNF treatment.
ivation or de novo infection in 98 patients within 6 to 30 months
atment.
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reliability of IGRAs?
Theperformanceof each IGRA is assessed through the use of
an internal control whichmeasures the IFN-γ response against
phytohaemagglutinin (PHA). A negative response against this
mitogen in the context of negative responses against the
M. tuberculosis-speciﬁc antigens renders the IGRA indetermi-
nate. This positive control becomes especially important in
testing persons with weakened cellular immunity. To date the
indeterminate rate of QuantiFERON®-TB Gold and Quanti-
FERON®-TB Gold in-tube in patients on immunosuppressive
therapy has been between 2% and 12% [19–22,25,26,38]. The
reported indeterminate rate of ELISpot was 0% in two studies
[24,32] and 5.8% in a third study [38], but the limited amount of
available data precludes drawing ﬁrm conclusions.
The apparent robustness of the technical performance and
diagnostic sensitivity of IGRAs in IMIDs on DMARDs contrasts
with the suppression of lymphoproliferative responses and
IFN-γ responses in 5-day ELISAs previously noted in these
populations [27]. This may reﬂect the fact that IGRAs measure
IFN-γ released ex vivo by effector T cells rather than T-cell
proliferation or IFN-γ released from cells that have undergone
proliferation [27–29].
6. Clinical performance of IGRAs in patients on
anti-TNF therapy
Three studies to date report on the performance of IGRAs
in patients already on anti-TNF agents. Neither corticosteroids
nor DMARDs signiﬁcantly affected the QFT-Gold in-tube
response in patients with inﬂammatory rheumatic condi-
tions, but the odds for a positive IFN-γ result were decreased
in patients treated with TNFα inhibitors [19]. In a second
study, the magnitude of the IFN-γ response measured by
ELISpot also signiﬁcantly decreased 14 weeks after the start of
anti-TNF treatment [27]. In a third recent study using QFT-G, 2
patients with positive IGRA results at 12 months of adalimu-
mab therapy developed active TB [39]. The performance of
IGRAs during anti-TNF treatment therefore needs to be
systematically assessed to determine whether these tests
can be used, if required, for regular screening of patients on
anti-TNF agents in high prevalence countries or after an
exposure event. In addition, alternative cytokine read-outs
should be assessed to see if they are more robust to TNF
blockade [30–32].
7. Concluding remarks
Published evidence on the performance of IGRAs suggests
that IGRAs maintain their diagnostic sensitivity for LTBI
better than TST in patients with IMID, most of whom are on
immunosuppressive DMARDs. Most of the available data to
date is derived from QFT-Gold in-tube and the evidence-base
for both this assay and T-SPOT.TB needs to be expanded to
assess whether these new tests are deﬁnitely superior to TST
in this important patient population. Also, next-generation
IGRAs that incorporate new M. tuberculosis-speciﬁc antigens
which signiﬁcantly enhance diagnostic sensitivity without
compromising speciﬁcity hold promise and should therefore
be assessed in this population [33]. The lack of a goldstandard for diagnosis of LTBI means that prospective
longitudinal clinical outcome studies to determine the
prognostic value of positive IGRA results for subsequent
development of active TB in this population are urgently
required.
In the meantime, some practical recommendations for
screening for TB infection prior to TNF blockade can be made.
Most importantly, active TB must ﬁrst be excluded by history
and chest radiograph. Screening for LTBI should include
checking for a history of untreated or partially treated TB, risk-
stratiﬁcation for exposure to cases of active TB and searching
for evidence of residual changes indicative of untreated prior
TB infection on a chest radiograph (e.g. calciﬁed granulomas,
Gohn focus or complex, apical scarring). In addition, given the
apparent diagnostic superiority of IGRAs over TST, one or the
other of the new blood tests should be performed. However,
given the very limited size of the evidence-base in support of
IGRAs to date and the vulnerability of these patients to
develop severe and disseminated forms of TB on TNF
blockade, it may be prudent to perform TST in parallel with
IGRA to maximise the diagnostic sensitivity of screening, at
least until the IGRA evidence-base in this population has
expanded sufﬁciently. Since some patients with LTBI may
have false-negative IGRA results and true-positive TST results,
while others will have true-positive IGRA results and false-
negative TST results, a dual-testing strategy should enable
physicians to offer all patients with LTBI preventative
treatment. IGRA results in patients already taking anti-TNF
agents currently remain uninterpretable.
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Take-home messages
• Testing for and treatment of latent tuberculosis infection
(LTBI) should be targeted to high risk groups who are at
increased risk of progression to active tuberculosis.
• Tumour necrosis factor alpha (TNFα) is a key cytokine in
protective host immunity against M. tuberculosis infection.
The risk of incident tuberculosis (TB) in patients latently
infected withM. tuberculosis increases substantially, from 4
to 5 fold over baseline in the case of inﬂiximab, after
initiation of anti-TNF therapy.
• TST is an inadequate tool for screening patients for LTBI
before commencing anti-TNFα agents because of poor
speciﬁcity in BCG-vaccinated individuals and poor sensitiv-
ity in patients with immune-mediated inﬂammatory dis-
eases (IMID) on conventional immunosuppressants e.g.
methotrexate and steroids.
• T-cell interferon-gamma release assays (IGRAs) detect
interferon-gamma (IFN-γ) released ex vivo from pre-
sensitised M. tuberculosis-speciﬁc T cells in response to
selected proteins which, unlike PPD, are highly speciﬁc for
151A. Lalvani, K.A. Millington / Autoimmunity Reviews 8 (2008) 147–152M. tuberculosis. Extensive published literature suggests that
IGRA are a more speciﬁc and probably a more sensitive test
for diagnosis of M. tuberculosis infection than the TST in
immunocompetent persons.
• The limited available published data in patients with IMID
on disease modifying antirheumatic drugs (DMARDs) who
are candidates for TNF blockade shows that IGRA results
agree poorly with TST results and are more closely
associated with the presence of risk factors for LTBI than
TST, suggesting that IGRAs maintain diagnostic sensitivity
for LTBI better than TST in this key population. However,
preliminary data suggests that in patients who are already
on anti-TNF treatment the IFN-γ response is signiﬁcantly
reduced and negative IGRA results should therefore not be
interpreted as implying absence of infection.
• IGRAs are a promising adjunct for screening patients with
IMID prior to TNF blockade, but more data are required to
validate their precise role in this setting.
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